Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women

Therapeutic Drug Monitoring

Volumn 33, Issue 5, 2011, Pages 619-626

  Concheiro, Marta ^a,b   Jones, Hendreé E ^c   Johnson, Rolley E ^c,d   Choo, Robin ^e   Huestis, Marilyn A ^b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RECKITT BENCKISER   (United Kingdom)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

buprenorphine; oral fluid; pharmacokinetics; plasma; pregnancy

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE GLUCURONIDE; DRUG METABOLITE; GLUCURONIDE; METHADONE; NORBUPRENORPHINE; NORBUPRENORPHINE GLUCURONIDE; OPIATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; GESTATIONAL AGE; HUMAN; OPIATE ADDICTION; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; SWEAT; TABLET FORMULATION;

AREA UNDER CURVE; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; POSTPARTUM PERIOD; PREGNANCY; SALIVA; SWEAT;

EID: 84860391245     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318228bb2a     Document Type: Article

References (37)

1. Huang W, Moody DE, McCance-Katz EF. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid-chromatography- electrospray ionization-tandem mass spectrometry. Ther Drug Monit. 2006;28:245-251. (Pubitemid 44314956)
2. Bullingham R, McQuay H, Porter E, et al. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol. 1982;13:665-673. (Pubitemid 13139882)
3. Marquet P. Pharmacology of high-dose buprenorphine. In: Kintz P, Marquet P, eds. Buprenorphinetherapy of Opiate Addiction. Totowa, NJ: Humana Press; 2002:1-11.
4. Iribarne C, Picart D, Dreano Y, et al. Involvement of cytochrome P450 3A in n-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997;60:1953-1964. (Pubitemid 27224184)
5. Rios G, Tephly T. Inhibition and active sites of UDP- glucuronosyltransferases 2B7 and 1A1. Drug Metab Dispos. 2002;30:1364-1367. (Pubitemid 35397039)
6. Rouguieg K, Picard N, Sauvage F-L, et al. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos. 2010;38:40-45.
7. Chawarski MC, Moody DE, Pakes J, et al. Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms. J Subst Abuse Treat. 2005;29:307-312. (Pubitemid 41711942)
8. Harris DS, Mendelson JE, Lin ET, et al. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone. Clin Pharmacokinet. 2004;43:329-340. (Pubitemid 38534755)
9. Compton P, Ling W, Moody D, et al. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend. 2006;82:25-31. (Pubitemid 43289101)
10. Everhart ET, Cheung P, Shwonek P, et al. Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: application to pharmacokinetics of sublingual buprenorphine. Clin Chem. 1997;43:2292-2302. (Pubitemid 28022964)
11. Schuh KJ, Johanson CE. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend. 1999;56:55-60. (Pubitemid 29295378)
12. Ciraulo DA, Hitzemann RJ, Somoza E, et al. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in doseescalation trials. J Clin Pharmacol. 2006;46:179-192. (Pubitemid 43146449)
13. McAleer SD, Mills RJ, Polack T, et al. Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid näve healthy male volunteers under naltrexone block. Drug Alcohol Depend. 2003;72:75-83. (Pubitemid 37255332)
14. Kuhlman JJ, Lalani S, Malguilo J, et al. Human pharmacokinetics of intravenous, sublingual, and bussal buprenorphine. J Anal Toxicol. 1996; 20:369-378. (Pubitemid 26327458)
15. Lejeune C, Simmat-Durand L, Gourarier L, et al. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend. 2006;82:250-257.
16. Fischer G. Treatment of opioid dependence in pregnant women. Addiction. 2000;95:1141-1144. (Pubitemid 30644100)
17. Dunlop A, Panjari M, O'Sullivan H, et al. Clinical Guidelines for the Use of Buprenorphine in Pregnancy. Fitzroy, Victoria: Turning Point Alcohol and Drug Centre; 2003.
18. Jones HE, Martin PR, Heil SH, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat. 2008; 35:245-259.
19. Reynolds F, Knott C. Pharmacokinetics in pregnancy and placental drug transfer. In: Milligan SR, ed. Oxford Reviews of Reproductive Biology, Vol Oxford, UK: Oxford University Press; 1989:389-449.
20. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44:989-1008. (Pubitemid 41356388)
21. Concheiro M, Jones HE, Johnson RE, et al. Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes. Ther Drug Monit. 2010;32:206-215.
22. de Castro A, Jones HE, Johnson RE, et al. Maternal methadone dose, placental methadone concentrations, and neonatal outcomes. Clin Chem. 2011;57:449-458.
23. Nanovskaya T, Deshmukh S, Brooks M, et al. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther. 2002;300:26-33. (Pubitemid 34028504)
24. Concheiro M, Jones HE, Johnson RE, et al. Umbilical cord monitoring of in utero drug exposure to buprenorphine and correlation with maternal dose and neonatal outcomes. J Anal Toxicol. 2010;34:498-505.
25. Davison JM, Dunlop W. Renal hemodynamics and tubular function normal human pregnancy. Kidney Int. 1980;18:152-61. (Pubitemid 11210512)
26. Pond J, Kreek MJ, Tong TG, et al. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther. 1985; 233:1-6. (Pubitemid 15083518)
27. Gerdin E, Salmonson T, Lindberg B, et al. Maternal kinetics of morphine during labour. J Perinat Med. 1990;18:479-487.
28. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79:1-10. (Pubitemid 41557119)
29. Signorini DF, Leung O, Simes RJ, et al. Dynamic balanced randomization for clinical trials. Stat Med. 1993;12:2343-2350. (Pubitemid 24007153)
30. Concheiro M, Jones H, Johnson RE, et al. Confirmatory analysis of buprenorpine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphinemaintained pregnant women. J Chromatogr B. 2010;878:13-20.
31. Concheiro M, Shakleya D, Huestis MA. Simultaneous analysis of buprenorphine, methadone, cocaine, opiates and nicotine metabolites in sweat by liquid chromatography tandem mass spectrometry. Anal Bioanal Chem. 2011;400:69-78.
32. Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis. 1991;163:226-232.
33. Tomson G, Lunell NO, Sundwall A, et al. Placental passage of oxazepam and its metabolism in mother and newborn. Clin Pharmacol Ther. 1979; 25:74-81. (Pubitemid 9111296)
34. Kacinko SL, Jones HE, Johnson RE, et al. Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment. Clin Chem. 2009;55:1177-1187.
35. Cone E, Dickerson SL, Darwin WD, et al. Elevated drug saliva levels suggest a "depot-like" effect in subjects treated with sublingual buprenorphine. In: Harris, ed. Problems of Drug Dependence 1990: Proceeding of the 52nd Annual Scientific Meeting. The Committee on Problems of Drug Dependence, Inc. Natl. Inst. Drug Abuse Res. Monogr. Ser. Rockville, MD: US Department of Health and Human Services; 1991:569.
36. Kintz P, Tracqui A, Mangin P, et al. Sweat testing in opioid users with a sweat patch. J Anal Toxicol. 1996;20:393-397. (Pubitemid 26327460)
37. Jones HE, Johnson RE, O'Grady KE, et al. Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. J Addict Med. 2008;2:103-107.